Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Acquires 24,900 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 24,900 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were bought at an average cost of $8.00 per share, with a total value of $199,200.00. Following the transaction, the director directly owned 18,404,086 shares in the company, valued at $147,232,688. This trade represents a 0.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

BNR stock opened at $9.82 on Friday. The business’s fifty day moving average price is $12.57 and its 200 day moving average price is $20.04. Burning Rock Biotech Limited Sponsored ADR has a 12-month low of $3.23 and a 12-month high of $41.72. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BNR. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

Several institutional investors have recently added to or reduced their stakes in BNR. Marshall Wace LLP acquired a new position in Burning Rock Biotech in the fourth quarter valued at approximately $220,000. Renaissance Technologies LLC raised its holdings in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares in the last quarter. Prospera Financial Services Inc raised its holdings in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Crcm LP lifted its position in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.